<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338039</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0983</org_study_id>
    <nct_id>NCT00338039</nct_id>
  </id_info>
  <brief_title>Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients</brief_title>
  <official_title>Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic&#xD;
      chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary&#xD;
      endpoint is actuarial one-year survival.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To evaluate the local tumor response in patients treated with the above regimen.&#xD;
&#xD;
        -  To characterize the safety of the above regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cetuximab is a drug that blocks epidermal growth factor receptor (EGFR). EGFR may be involved&#xD;
      in certain types of cancer. When EGFR is stimulated, a series of chemical reactions starts&#xD;
      that results in a tumor being &quot;told&quot; to grow. Cetuximab tries to stop these reactions by&#xD;
      blocking EGFR. This may stop tumors from growing. Cetuximab has been shown to increase the&#xD;
      effect of chemotherapy and of radiation therapy, both of which will also be given in this&#xD;
      study.&#xD;
&#xD;
      Before you can start treatment on this study, you will have what are called &quot;screening&#xD;
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in the&#xD;
      study. You will have a complete medical history and physical exam. Blood (about 2&#xD;
      tablespoons) and urine will be collected for routine tests. Chest x-rays and computed&#xD;
      tomography (CT) scans of the abdomen will be done. Women who are able to have children must&#xD;
      have a negative urine pregnancy test.&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will first receive cetuximab&#xD;
      every 2 weeks for 8 weeks (4 doses). Cetuximab will be given every 2 weeks throughout the&#xD;
      duration of the study. Cetuximab will be continued during the radiation and capecitabine&#xD;
      combination, during the retesting stage and then during the chemotherapy that is given after&#xD;
      radiation therapy. Cetuximab infusions will be given over approximately 2 hours. Gemcitabine&#xD;
      and oxaliplatin chemotherapy will be given once every 2 weeks (4 doses) for 8 weeks. Both&#xD;
      drugs are given through a central line and over about 2 hours. Cetuximab will be given first,&#xD;
      followed by gemcitabine, and then followed by oxaliplatin. A CT scan and chest X-ray will be&#xD;
      done 2 weeks after the last dose (at Week 10).&#xD;
&#xD;
      As long as the tumor has not grown or spread, you will then receive cetuximab, capecitabine,&#xD;
      and radiation therapy together. The Capecitabine will be given by mouth twice a day every day&#xD;
      of radiation therapy (5 and 1/2 weeks). Radiation therapy will be given once a day for 5 days&#xD;
      in a row. It will be given for 5 and 1/2 weeks or 28 treatments. The radiation will be given&#xD;
      from 4 directions and focused on the tumor while you are lying on your back. You will&#xD;
      continue to receive cetuximab by vein once every 2 weeks during capecitabine and radiation&#xD;
      therapy.&#xD;
&#xD;
      After radiotherapy, you will continue to take cetuximab by vein every 2 weeks. The effect of&#xD;
      treatment will be evaluated 5-6 weeks after the completion of radiation therapy and&#xD;
      capecitabine. A chest x-ray and CT scans will be performed, and about 2 tablespoons of blood&#xD;
      will be drawn for routine testing. As long as the tumor has not grown or spread and the side&#xD;
      effects are not too severe, you may continue to receive Cetuximab by vein once every 2 weeks&#xD;
      . You will also receive Gemcitabine by vein in the same dose as before for 3 out of every 4&#xD;
      weeks as long as the tumor does not grow and the side effects are not too severe. CT scans&#xD;
      and chest x-rays will then be done every 2 months to evaluate the status of the tumor.&#xD;
&#xD;
      During the study, you will have physical exams, including weekly blood tests (about 2&#xD;
      tablespoons) each. The possible development of side effects will be closely monitored and&#xD;
      could require extra blood and/or urine samples.&#xD;
&#xD;
      You will be taken off study if your disease gets worse or intolerable side effects occur. You&#xD;
      may have surgery if at any time during therapy the tumor can be removed surgically. A&#xD;
      separate consent form will be used for that situation.&#xD;
&#xD;
      This is an investigational study. Capecitabine, oxaliplatin, and cetuximab are approved by&#xD;
      the FDA for colon cancer but have not been approved by the FDA for pancreatic cancer. Up to&#xD;
      69 patients will take part in this multicenter study. Up to 60 will be enrolled at M. D.&#xD;
      Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>1 to 4 years</time_frame>
    <description>1-year, 2-year, and 4-year actuarial overall survival (OS) rates defined as number of participants out of total participants alive at 1, 2 or 4 years post baseline treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Baseline to disease progression or death, up to 4 years</time_frame>
    <description>Median survival is defined as the time of initiation of the first dose of chemotherapy to the date of death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.</description>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <other_name>C225</other_name>
    <other_name>Erbitux</other_name>
    <other_name>IMC-C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Induction Therapy: 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.&#xD;
Chemotherapy Maintenance: 1 gm/m^2/week over 100 minutes weekly for 3 weeks then 1 week off.</description>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Gemcitabine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Induction Chemotherapy: 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.</description>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation.</description>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
    <arm_group_label>Chemotherapy + Chemoradation</arm_group_label>
    <other_name>XRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cytologic or histologic proof of adenocarcinoma of the pancreas is required prior to&#xD;
             treatment. Patients can have tumor originating in any part of the pancreas. Islet cell&#xD;
             tumors are not eligible. Only patients with non- metastatic, unresectable disease&#xD;
             (AJCC 2002 stage T4 NX M0) are eligible. Computed Tomography (CT) findings of lung,&#xD;
             liver, peritoneal metastasis are equivocal, are eligible. Patients who cannot undergo&#xD;
             resection because of underlying medical problems are also eligible. Diagnosis of&#xD;
             Pancreatic Adenocarcinoma by bile duce brushings are acceptable. Patients with&#xD;
             regional nodal disease are eligible.&#xD;
&#xD;
          2. All patients must be staged with a physical exam, chest X-ray (CXR), and&#xD;
             contrast-enhanced helical thin-cut abdominal CT. Unresectability is defined by CT&#xD;
             criteria: a) evidence of tumor extension to the celiac axis or superior mesenteric&#xD;
             (SM) artery, or b) evidence on either CT or angiogram of occlusion of the SM vein or&#xD;
             SM/ portal vein confluence. If a tumor does not meet this definition and is found to&#xD;
             be unresectable at surgical exploration, then that tumor is considered unresectable.&#xD;
&#xD;
          3. Patients must be 18 years and older. There will be no upper age restriction&#xD;
&#xD;
          4. Karnofsky performance status greater than or equal to 70 are eligible.&#xD;
&#xD;
          5. Patients must either be not of child bearing potential or have a negative urine&#xD;
             pregnancy test within 72 hours of treatment. Patients are considered not of child&#xD;
             bearing potential if they are surgically sterile (they have undergone a hysterectomy,&#xD;
             bilateral tubal ligation or bilateral oophorectomy) or they have been postmenopausal&#xD;
             for at least 12 months.&#xD;
&#xD;
          6. Women of childbearing potential must agree to practice adequate contraception and to&#xD;
             refrain from breast-feeding, as specified in the informed consent. Sexually active&#xD;
             males must practice contraception during the study.&#xD;
&#xD;
          7. Bone marrow function: absolute neutrophil count (ANC) &gt;1,500/ul. Platelets&#xD;
             &gt;100,000/ul.&#xD;
&#xD;
          8. Renal function: creatinine clearance &gt;30 mL/min (calculated with Cockcroft-Gault&#xD;
             equation).&#xD;
&#xD;
          9. Hepatic function: Total bilirubin less than 5mg/dL. If the patient required an&#xD;
             endobiliary stent, the bilirubin level must have declined on consecutive measurements&#xD;
             indicating adequate biliary decompression; alanine aminotransferase (ALT) less than or&#xD;
             equal to 5 times the upper limit of normal.&#xD;
&#xD;
         10. Neurologic function: neuropathy (sensory) &lt; Common Toxicity Criteria (CTC) Grade 2.&#xD;
&#xD;
         11. Patients must sign a study-specific consent form, which is attached to this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of prior metastatic cancer.&#xD;
&#xD;
          2. Patients must not have significant infection,i.e., requiring intravenous (IV)&#xD;
             antibiotics, or other coexistent medical condition that would preclude protocol&#xD;
             therapy.&#xD;
&#xD;
          3. Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,&#xD;
             unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled&#xD;
             congestive heart failure, and cardiomyopathy with ejection fraction less than &lt;30%.&#xD;
&#xD;
          4. Prior therapy which specifically and directly targets the estimated EGFR pathway.&#xD;
&#xD;
          5. Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension)&#xD;
             to a monoclonal antibody.&#xD;
&#xD;
          6. Any prior history of radiotherapy to the abdomen.&#xD;
&#xD;
          7. History or evidence upon physical examination of central nervous system (CNS) disease&#xD;
             (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any&#xD;
             brain metastases, or history of stroke)&#xD;
&#xD;
          8. Prior unanticipated severe reaction to fluoropyrimidine therapy or known&#xD;
             hypersensitivity to 5-fluorouracil.&#xD;
&#xD;
          9. Patients who have had an organ allograft.&#xD;
&#xD;
         10. Patients on Coumadin must be changed to Lovenox at least 1 week prior to starting&#xD;
             capecitabine. Low dose (1 mg) Coumadin is allowed.&#xD;
&#xD;
         11. Patients taking Sorivudine or Brivudine A must be off of these drugs for 4 weeks prior&#xD;
             to starting capecitabine. Patients taking cimetidine must have this drug discontinued.&#xD;
             Ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine&#xD;
             if necessary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher H. Crane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas (UT) MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>June 26, 2012</results_first_submitted>
  <results_first_submitted_qc>February 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>February 18, 2013</last_update_submitted>
  <last_update_submitted_qc>February 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>C225</keyword>
  <keyword>Erbitux</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Eloxatin</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: September 15, 2005 to June 29, 2009. All recruitment done at hospital and medical clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chemotherapy + Chemoradation</title>
          <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Grey delivered in 28 fractions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chemotherapy + Chemoradation</title>
          <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="39" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival Rate</title>
        <description>1-year, 2-year, and 4-year actuarial overall survival (OS) rates defined as number of participants out of total participants alive at 1, 2 or 4 years post baseline treatment.</description>
        <time_frame>1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Chemoradation</title>
            <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate</title>
          <description>1-year, 2-year, and 4-year actuarial overall survival (OS) rates defined as number of participants out of total participants alive at 1, 2 or 4 years post baseline treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year OS Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-year OS Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-year OS Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival</title>
        <description>Median survival is defined as the time of initiation of the first dose of chemotherapy to the date of death.</description>
        <time_frame>Baseline to disease progression or death, up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chemotherapy + Chemoradation</title>
            <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Median survival is defined as the time of initiation of the first dose of chemotherapy to the date of death.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" lower_limit="14.2" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chemotherapy + Chemoradation</title>
          <description>Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>normocytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>allergic reaction during infusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis/Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>associated with anorexia</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher H. Crane, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

